JenaValve Technology, Inc., a Munich, Germany and Irvine, California-based developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, completed a $26.5m Series C expansion round of financing.
The round was co-led by RMM (Rudi Mariën) and Valiance with participation from the existing syndicate of Atlas Venture, Edmond de Rothschild Investment Partners, Gimv, Legend Capital, NeoMed Management and VI Partners.
The company intends to use the proceeds for further growth in the global TAVR market.
Led by Victoria E. Carr-Brendel, Ph.D., chief executive officer, JenaValve develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems to treat patients suffering from aortic valve disease.
Its Transapical TAVR system, consisting of the JenaValve valve system plus Cathlete PLUS delivery system, has CE Mark approval for aortic valve stenosis and for the indication to treat patients suffering from aortic valve insufficiency.
JenaValve currently markets this product in Europe and other selected markets worldwide.